Search Results
Your search for Men matches 2763 pages
Showing 351 - 400
Jamie Takayesu, MD, on Genitourinary Cancer: Disparity in Physicians’ Assessment of Sexual Dysfunction in Women vs Men
Jamie Takayesu, MD, of the University of Michigan, discusses her findings on how frequently physicians are asking their female and male patients with genitourinary cancers about sexual dysfunction. Although 62.79% of women with genitourinary cancer who received brachytherapy thought they should be ...
Alex K. Bryant, MD, on PSA Screening and Metastatic Prostate Cancer in the VA Health-Care System
Alex K. Bryant, MD, of the University of Michigan, examined Veterans Administration (VA) facilities in which lower prostate-specific antigen (PSA) screening rates were associated with a subsequent increased incidence of metastatic prostate cancer, particularly among men aged 70 and older. From...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
PSMA-PET/CT May Help Improve Clinical Treatment of Prostate Cancer
A trial conducted at the University Hospital Bonn, Germany, has been testing the benefit of PSMA-PET/CT (prostate-specific membrane antigen–positron-emission tomography/computed tomography) to help target where to take biopsy samples, potentially improving the diagnosis of prostate cancer by giving ...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
Study Reveals New Understanding of How Androgen Therapy Affects Breast Tissue
Molecular changes observed in the breast tissue of transgender men undergoing androgen therapy may signal the potential for also using the hormone to prevent or treat estrogen receptor–positive breast cancer. The findings were published by Raths et al in Cell Genomics. “These findings build upon...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
'Don't Blame the Test'
“There are misconceptions about prostate cancer screening,” Karen Knudsen, MBA, PhD, said in an interview with The ASCO Post about newly published cancer statistics, including an increased incidence of prostate cancer, particularly advanced-stage disease. Dr. Knudsen is Chief Executive Officer of...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Working Together to Close the Global Care Gap
The COVID-19 pandemic has underscored that public health is the product of one global, integrated ecosystem. Although it is tempting to focus on specific aspects of local health-care systems, or the political or physical environment, health and health care in other countries also impacts the United ...
Study Finds Cancer Screening in the United States Lagged During the Second Year of the COVID-19 Pandemic
In a study reported in the Journal of Clinical Oncology, Star et al found that cancer screening remained below prepandemic levels in the United States during the second year of the COVID-19 pandemic. Study Details Data on past-year receipt of age-eligible screening for breast cancer (women aged 50...
FDA Expands Early Breast Cancer Indication for Abemaciclib Plus Endocrine Therapy
On March 3, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at high risk of...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Understanding the Health Disparities That Sexual and Gender Minorities Face in Oncology Care
In its programming for the 2022 ASCO Annual Meeting, ASCO included a special Education Session on “Gender-Based and Sexual Orientation Inequities: Promoting Inclusion, Visibility, and Data Accuracy in Oncology.” The session offered a comprehensive discussion on the challenges that sexual and gender ...
Adding Talazoparib to Enzalutamide Extends Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
TALAPRO-2: Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
New Study Calls for LGBTQIA+ Community Inclusion in Stem Cell Donor Recruitment
Researchers have highlighted the barriers to stem cell donation impacting LGBTQIA+ individuals and the efforts needed to build more inclusive donor recruitment practices and offered guidance for donor recruitment organizations, registries, and transplant centers worldwide to advance a more...
Pancreatic Cancer Rates May Be Rising Faster Among Younger Women Than Younger Men
Investigators have confirmed that rates of pancreatic cancer are rising overall, but they are rising faster among younger female patients—particularly among patients who identified as Black—than among male patients of the same age, according to a new study published by Abboud et al in...
Diagnosis, Treatment, and Outcomes of Breast Cancer in Patients From Sex and Gender Minority Groups
In a single-institution study reported in JAMA Oncology, Eckhert et al found that patients with breast cancer from sex and gender minority groups experienced delayed diagnosis and had a shorter time to cancer recurrence compared to cisgender heterosexual patients. Study Details In the...
Continued Declines in Cancer Mortality and Reductions in Cervical Cancer Incidence, but Increases in Advanced Prostate Cancer and Persistent Racial Disparities
The American Cancer Society (ACS) has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths, according to the report. Data in the report also showed that women between the ages of 20 and...
FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, the U.S. Food and Drug Administration (FDA) approved elacestrant (Orserdu) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine...
Determining the Role of Muscadine Grape Skin Extract in Treating Prostate Cancer
Oxidative stress is a key factor in the development of many diseases including cancer. Antioxidants prevent cellular damage by neutralizing free radicals and are being investigated as potential therapeutic strategies against cancer. In this installment of The ASCO Post’s Integrative Oncology...
A Serendipitous Opportunity Steers a Theater Major Into Oncology
Lymphoma expert Jeremy S. Abramson, MD, was born in Westchester County, New York, but soon after, his family relocated to Bergen County, New Jersey, where he spent his formative years. “I attended Tenafly High School and had dual passions: one was the natural sciences and the other on the...
American Cancer Society’s Cancer Statistics 2023 Report Released
The American Cancer Society has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths. Data in the report, which was published by Siegel et al in CA: A Cancer Journal for Clinicians, also ...
Older Minority Patients With Cancer Face Inequities in Opioid Access Near the End of Life
Research shows that pain is a common byproduct of cancer and its treatment, with approximately 55% of patients undergoing active treatment experiencing pain, and more than 66% of patients with advanced disease experiencing pain. According to the ASCO guideline on the use of opioids for adults with...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States
In a study reported in the Journal of Clinical Oncology, Damgacioglu et al found that squamous cell carcinoma of the anus incidence and mortality rates increased in men and women aged ≥ 50 years at diagnosis between 2001 to 2005 and 2014 to 2018, with increases concentrated in Midwestern and...
ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer
A new ASCO guideline on the management of advanced colorectal cancer summarizes the latest treatments supported by quality data that could expand oncologists’ armamentarium and potentially improve survival outcomes.1 “[Colorectal cancer] remains the second-leading class of cancer deaths among men ...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
Expert Point of View: Iris C. Gibbs, MD, FACR, FASTRO and Sophia C. Kamran, MD
Iris C. Gibbs, MD, FACR, FASTRO, of Stanford Medicine in California and Chair of the American Society for Radiation Oncology (ASTRO) Council on Health Equity, Diversity, and Inclusion, was an invited discussant for this study on physician assessment of sexual dysfunction in women vs men receiving...
Sexual Side Effects of Radiotherapy for Genitourinary Cancers: Is Physician Assessment Equitable for Women and Men?
Many radiation oncologists tend to discuss the sexual side effects of radiation therapy, specifically brachytherapy, with men more often than with women, according to a two-part study reported at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 At a high-volume cancer...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
Adjuvant Pembrolizumab May Improve Quality of Life in Patients With High-Risk Resected Melanoma
Taken together with the primary clinical results, a secondary analysis of the phase III SWOG S1404 randomized clinical trial demonstrated that pembrolizumab provides superior clinical and patient-reported quality-of-life outcomes compared to standard of care with adjuvant ipilimumab or high-dose...
Annual Report to the Nation: Cancer Deaths Continue Downward Trend
OVERALL CANCER death rates continued to decline among men, women, children, and adolescents/young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer.1 From 2014 to 2018, the overall cancer ...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...
Addition of Enzalutamide to Salvage Radiotherapy in Patients With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
In a phase II trial (SALV-ENZA) reported in the Journal of Clinical Oncology, Phuoc T. Tran, MD, PhD, and colleagues found that the addition of enzalutamide to salvage radiotherapy improved freedom from prostate-specific antigen (PSA) progression in patients with biochemically recurrent prostate...
ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA
An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
Sequencing of Short-Duration ADT With Radiotherapy in Nonmetastatic Prostate Cancer
In a pooled analysis (SANDSTORM) reported in the Journal of Clinical Oncology, Ma et al found that concurrent/adjuvant short-term androgen-deprivation therapy (ADT) with prostate-only radiotherapy (PORT) was associated with better outcomes in multiple measures vs neoadjuvant/concurrent ADT with...
Biomarker Assessment for Benefit of LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
In a prespecified analysis from the Australian phase II TheraP trial reported in The Lancet Oncology, Buteau et al found that higher gallium-68–labeled PSMA-11 positron-emission tomography (PSMA-PET) mean standardized uptake values (SUVmean) were associated with a greater likelihood of...
Effect of Invitation to Colonoscopy Screening on Risk of Colorectal Cancer and Risk of Mortality: The NordICC Trial
In a pragmatic trial reported in The New England Journal of Medicine, Bretthauer et al, on behalf of the Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group, found a reduced risk of colorectal cancer diagnosis but no significant reduction in disease-specific mortality among...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Highlights From the ESMO Congress 2022
At this year’s European Society for Medical Oncology (ESMO) Congress, we experienced an eagerly awaited return to normality (or almost), and the quality of the science on display was anything but disappointing: from molecular medicine to treatment de-escalation, from early cancer detection and...
Addition of Cediranib to Olaparib for Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim et al, the phase II National Cancer Institute 9984 trial has shown prolonged radiographic progression-free survival with the addition of cediranib to olaparib in patients with metastatic castration-resistant prostate cancer. Study Details In...
Multimodal Artificial Intelligence Models May Offer an Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer
NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal artificial intelligence models (MMAI) that could outperform the National Comprehensive Cancer...
